Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease

  • Woo, Min Hyung (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Cho, Young Hoon (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Sohn, Min Ji (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Eun Joo (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Ju Whi (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Moon, Jin Soo (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Ko, Jae Sung (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Hyun-young (Department of Surgery, Seoul National University Children's Hospital, Seoul National University College of Medicine)
  • Received : 2018.10.08
  • Accepted : 2018.11.01
  • Published : 2019.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Pediatric Crohn's disease (CD) is directly related to growth and has a high probability of requiring surgical intervention(s); therefore, more active treatment for CD is required for children. This study investigated the impact of biologics on growth and disease course associated with surgery. Methods: This was a retrospective cohort study involving patients diagnosed with CD at the Seoul National University Children's Hospital (Seoul, Korea) between January 2006 and October 2017. The aim was to determine the characteristics of pediatric patients with CD and whether biologics affected growth and the surgical disease course. Results: Among patients who underwent surgery for CD, the mean number of operations per patient was 1.89. The mean time from initial diagnosis to surgery was 19.3 months. The most common procedure was fistulectomy (34%), followed by incision and drainage (25%). In all patients, the use of biologics increased the height (p=0.002) and body mass index (BMI) (p=0.005). Among patients who underwent surgery, height (p=0.004) and BMI (p=0.048) were increased in the group using biologics. Patients who used biologics exhibited a low operation rate only within 2 years after diagnosis, with no differences thereafter (p=0.027). Conclusion: Although biologics could not mitigate the operation rate in pediatric patients who underwent surgery for CD, biological therapy delayed disease progression within 2 years of disease onset. Additionally, biologics conferred growth and BMI benefits in this window period. Therefore, it may be helpful to use biologics for optimal growth in pediatric patients with a high probability of undergoing future surgery.

Keywords

References

  1. Lee YJ, Oh SH, Kim KM. The principles of drug therapy of Crohn's disease in child and adolescent. Korean J Pediatr Gastroenterol Nutr 2010;13:S59-69. https://doi.org/10.5223/kjpgn.2010.13.Suppl1.S59
  2. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui A, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology 2013;145:158-165.e2. https://doi.org/10.1053/j.gastro.2013.04.007
  3. Polito JM 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580-6. https://doi.org/10.1053/gast.1996.v111.pm8780560
  4. Cuffari C, Dubinsky M, Darbari A, Sena L, Baldassano R. Crohn's jejunoileitis: the pediatrician's perspective on diagnosis and management. Inflamm Bowel Dis 2005;11:696-704. https://doi.org/10.1097/01.MIB.0000166933.74477.69
  5. Lee YA, Chun P, Hwang EH, Mun SW, Lee YJ, Park JH. Clinical features and extraintestinal manifestations of Crohn disease in children. Pediatr Gastroenterol Hepatol Nutr 2016;19:236-42. https://doi.org/10.5223/pghn.2016.19.4.236
  6. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106-13. https://doi.org/10.1053/j.gastro.2008.06.079
  7. Kim S. Surgery in pediatric Crohn's disease: indications, timing and post-operative management. Pediatr Gastroenterol Hepatol Nutr 2017;20:14-21. https://doi.org/10.5223/pghn.2017.20.1.14
  8. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 2006;118:124-9. https://doi.org/10.1542/peds.2005-2931
  9. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988;95:1523-7. https://doi.org/10.1016/S0016-5085(88)80072-6
  10. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004:CD003574.
  11. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301. https://doi.org/10.1002/ibd.20927
  12. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42. https://doi.org/10.1016/j.gie.2005.08.011
  13. Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-7. https://doi.org/10.1016/j.dld.2003.12.014
  14. Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-$\alpha$ vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014;146:383-91. https://doi.org/10.1053/j.gastro.2013.10.027
  15. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9. https://doi.org/10.1053/j.gastro.2005.01.048
  16. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002;45:771-5. https://doi.org/10.1007/s10350-004-6296-8
  17. Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, et al. Long-term outcome of early combined immunosuppression versus conventional management in newly diagnosed Crohn's disease. J Crohns Colitis 2018;12:517-24. https://doi.org/10.1093/ecco-jcc/jjy014
  18. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9. https://doi.org/10.1111/j.1572-0241.2001.03612.x
  19. de Onis M, Garza C, Victora CG, Onyango AW, Frongillo EA, Martines J. The WHO multicentre growth reference study: planning, study design, and methodology. Food Nutr Bull 2004;25:S15-26. https://doi.org/10.1177/15648265040251S104
  20. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007;85:660-7. https://doi.org/10.2471/BLT.07.043497
  21. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47. https://doi.org/10.1097/00005176-199105000-00005
  22. Hassan K, Cowan FJ, Jenkins HR. The incidence of childhood inflammatory bowel disease in Wales. Eur J Pediatr 2000;159:261-3. https://doi.org/10.1007/s004310050066
  23. Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007;42:602-10. https://doi.org/10.1080/00365520601076124
  24. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, Dupas JL, Merle V, Merlin B, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010;105:1893-900. https://doi.org/10.1038/ajg.2010.20
  25. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179-207. https://doi.org/10.1016/j.crohns.2014.04.005
  26. Malik S, Ahmed SF, Wilson ML, Shah N, Loganathan S, Naik S, et al. The effects of anti-TNF-$\alpha$ treatment with adalimumab on growth in children with Crohn's disease (CD). J Crohns Colitis 2012;6:337-44. https://doi.org/10.1016/j.crohns.2011.09.004
  27. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007;13:424-30. https://doi.org/10.1002/ibd.20069
  28. Assa A, Hartman C, Weiss B, Broide E, Rosenbach Y, Zevit N, et al. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis 2013;7:369-76. https://doi.org/10.1016/j.crohns.2012.03.006
  29. Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn's disease. Nat Rev Gastroenterol Hepatol 2009;6:513-23. https://doi.org/10.1038/nrgastro.2009.124
  30. Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008;12:1738-44. https://doi.org/10.1007/s11605-008-0646-0
  31. Sakatani A, Fujiya M, Ito T, Inaba Y, Ueno N, Kashima S, et al. Infliximab extends the duration until the first surgery in patients with Crohn's disease. Biomed Res Int 2013;2013:879491.
  32. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007:CD000542.

Cited by

  1. Increased Use of Anti-Tumor Necrosis Factor Following the Implementation of the ECCO-ESPGHAN Guidelines and its Impact on the Outcome of Pediatric Crohn's Disease: A Retrospective Single-Center Study vol.74, pp.1, 2022, https://doi.org/10.1097/mpg.0000000000003301